PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
May 07, 2024 08:30 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a...
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
May 07, 2024 08:00 ET
|
Oragenics
SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a...
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
April 16, 2024 16:30 ET
|
PaxMedica, Inc.
Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously...
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
March 13, 2024 08:20 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today...
NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13
February 08, 2024 15:30 ET
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
Deep Brain Stimulation Devices Market to Witness USD 3.5 Billion Expansion by 2033, Driven by Surging Demand and Ongoing Research Advancements
January 11, 2024 06:55 ET
|
Market.Us
New York, Jan. 11, 2024 (GLOBE NEWSWIRE) -- According to market.us, the Deep Brain Stimulation Devices Market is expected to reach around USD 3.5 Billion by 2033, indicating substantial growth...
PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data
November 17, 2023 08:00 ET
|
PaxMedica, Inc.
LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN –PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that...
Nerve Repair and Regeneration Market Size Worth USD 14.21 Billion in 2032 | Emergen Research
November 15, 2023 12:55 ET
|
Emergen Research
Vancouver, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The global Nerve Repair and Regeneration Market will be worth USD 14.21 Billion by 2032, according to a current analysis by Emergen Research. The growth...
PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
October 31, 2023 08:00 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological...
NeuroOne® to Present at the ThinkEquity Conference on October 19, 2023
October 13, 2023 09:30 ET
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Oct. 13, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...